Renaissance Technologies's VRTX Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 735,888 shares of Vertex Pharmaceuticals Incorporated (VRTX) worth $288.2 M, representing 0.38% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 49 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in VRTX, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2017, adding 1.48 M shares. Largest reduction occurred in Q4 2020, reducing 1.63 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Vertex Pharmaceuticals Incorporated (VRTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Vertex Pharmaceuticals Incorporated (VRTX) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2013 | +139,220 | New Buy | 139,220 | $75.82 |
| Q4 2013 | -139,220 | Sold Out | 139,220 | $0.00 |
| Q1 2014 | +312,164 | New Buy | 312,164 | $70.72 |
| Q2 2014 | -312,164 | Sold Out | 312,164 | $0.00 |
| Q1 2015 | +159,317 | New Buy | 159,317 | $117.97 |
| Q2 2015 | -159,317 | Sold Out | 159,317 | $0.00 |
| Q4 2015 | +61,317 | New Buy | 61,317 | $125.84 |
| Q1 2016 | +51,300 | Add 83.66% | 112,617 | $79.49 |
| Q2 2016 | -52,100 | Reduce 46.26% | 60,517 | $86.03 |
| Q3 2016 | -60,517 | Sold Out | 60,517 | $0.00 |
| Q1 2017 | +40,117 | New Buy | 40,117 | $109.36 |
| Q2 2017 | -18,417 | Reduce 45.91% | 21,700 | $128.85 |
| Q3 2017 | +1.35 M | Add 6204.24% | 1.37 M | $152.04 |
| Q4 2017 | +1.48 M | Add 108.18% | 2.85 M | $149.86 |
| Q1 2018 | +3,000 | Add 0.11% | 2.85 M | $162.98 |
| Q2 2018 | +1.2 M | Add 42.08% | 4.05 M | $169.96 |
| Q3 2018 | +38,500 | Add 0.95% | 4.09 M | $192.74 |
| Q4 2018 | +245,183 | Add 6.00% | 4.33 M | $165.71 |
| Q1 2019 | +744,417 | Add 17.18% | 5.08 M | $183.95 |
| Q2 2019 | +477,100 | Add 9.39% | 5.56 M | $183.38 |
| Q3 2019 | +243,300 | Add 4.38% | 5.8 M | $169.42 |
| Q4 2019 | +1.28 M | Add 22.03% | 7.08 M | $218.95 |
| Q1 2020 | -216,900 | Reduce 3.07% | 6.86 M | $237.95 |
| Q2 2020 | -1.08 M | Reduce 15.72% | 5.78 M | $290.31 |
| Q3 2020 | -574,400 | Reduce 9.94% | 5.21 M | $272.12 |
| Q4 2020 | -1.63 M | Reduce 31.32% | 3.58 M | $236.34 |
| Q1 2021 | -1.18 M | Reduce 32.88% | 2.4 M | $214.89 |
| Q2 2021 | -123,000 | Reduce 5.12% | 2.28 M | $201.63 |
| Q3 2021 | -385,798 | Reduce 16.94% | 1.89 M | $181.39 |
| Q4 2021 | -264,618 | Reduce 13.99% | 1.63 M | $219.60 |
| Q1 2022 | +80,500 | Add 4.95% | 1.71 M | $260.97 |
| Q2 2022 | +53,800 | Add 3.15% | 1.76 M | $281.79 |
| Q3 2022 | +377,717 | Add 21.45% | 2.14 M | $289.54 |
| Q4 2022 | +107,867 | Add 5.04% | 2.25 M | $0.29 |
| Q1 2023 | -849,017 | Reduce 37.79% | 1.4 M | $0.32 |
| Q2 2023 | -125,574 | Reduce 8.98% | 1.27 M | $0.35 |
| Q3 2023 | +391,927 | Add 30.81% | 1.66 M | $347.74 |
| Q4 2023 | -72,400 | Reduce 4.35% | 1.59 M | $406.89 |
| Q1 2024 | -11,200 | Reduce 0.70% | 1.58 M | $418.01 |
| Q2 2024 | -14,100 | Reduce 0.89% | 1.57 M | $468.72 |
| Q3 2024 | +65,105 | Add 4.16% | 1.63 M | $465.08 |
| Q4 2024 | -234,284 | Reduce 14.36% | 1.4 M | $402.70 |
| Q1 2025 | -225,638 | Reduce 16.15% | 1.17 M | $484.82 |
| Q2 2025 | -166,683 | Reduce 14.23% | 1 M | $445.20 |
| Q3 2025 | -269,000 | Reduce 26.77% | 735,888 | $391.64 |
Renaissance Technologies's Vertex Pharmaceuticals Incorporated Investment FAQs
Renaissance Technologies first purchased Vertex Pharmaceuticals Incorporated (VRTX) in Q3 2013, acquiring 139,220 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Vertex Pharmaceuticals Incorporated (VRTX) for 49 quarters since Q3 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to Vertex Pharmaceuticals Incorporated (VRTX) was in Q4 2017, adding 2,847,917 shares worth $426.79 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 735,888 shares of Vertex Pharmaceuticals Incorporated (VRTX), valued at approximately $288.2 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Vertex Pharmaceuticals Incorporated (VRTX) represents approximately 0.38% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in Vertex Pharmaceuticals Incorporated (VRTX) was 7,076,582 shares, as reported at the end of Q4 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.